Severe COVID-19 Complicated by Cerebral Venous Thrombosis in a Newborn Successfully Treated with Remdesivir, Glucocorticoids, and Hyperimmune Plasma

Int J Environ Res Public Health. 2021 Dec 15;18(24):13201. doi: 10.3390/ijerph182413201.

Abstract

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is responsible for the coronavirus disease 2019 (COVID-19) pandemic, affecting all age groups with a wide spectrum of clinical presentation ranging from asymptomatic to severe interstitial pneumonia, hyperinflammation, and death. Children and infants generally show a mild course of the disease, although infants have been observed to have a higher risk of hospitalization and severe outcomes. Here, we report the case of a preterm infant with a severe form of SARS-CoV-2 infection complicated by cerebral venous thrombosis successfully treated with steroids, hyperimmune plasma, and remdesivir.

Keywords: COVID-19; SARS-CoV-2; cerebral thrombosis; newborn; remdesivir.

Publication types

  • Case Reports

MeSH terms

  • Adenosine Monophosphate / analogs & derivatives
  • Alanine / analogs & derivatives
  • COVID-19 Drug Treatment*
  • Child
  • Glucocorticoids / therapeutic use
  • Humans
  • Infant
  • Infant, Newborn
  • Infant, Premature
  • SARS-CoV-2
  • Venous Thrombosis* / drug therapy

Substances

  • Glucocorticoids
  • remdesivir
  • Adenosine Monophosphate
  • Alanine